Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Interest & Investment Income (2017 - 2025)

Historic Interest & Investment Income for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $3.7 million.

  • Dianthus Therapeutics' Interest & Investment Income fell 1770.53% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.8 million, marking a year-over-year decrease of 617.61%. This contributed to the annual value of $17.4 million for FY2024, which is 26450.46% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Interest & Investment Income of $3.7 million as of Q3 2025, which was down 1770.53% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Interest & Investment Income registered a high of $4.7 million during Q2 2024, and its lowest value of $416000.0 during Q3 2022.
  • In the last 4 years, Dianthus Therapeutics' Interest & Investment Income had a median value of $3.4 million in 2025 and averaged $2.6 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first surged by 59669.97% in 2024, then plummeted by 2771.88% in 2025.
  • Dianthus Therapeutics' Interest & Investment Income (Quarter) stood at $640000.0 in 2022, then soared by 281.88% to $2.4 million in 2023, then soared by 63.26% to $4.0 million in 2024, then fell by 8.32% to $3.7 million in 2025.
  • Its Interest & Investment Income stands at $3.7 million for Q3 2025, versus $3.4 million for Q2 2025 and $3.8 million for Q1 2025.